Some recent recipients of US Food and Drug Administration warnings probably wouldn’t have any reason to anticipate contact from the agency if they weren’t attempting to capitalize on consumer fear about COVID-19. When businesses rapidly pivot to offering consumer health products and services, though, they’re likely not contemplating compliance with the FDA’s regulations.
Recent warning letters the agency published are more proof that the novel coronavirus 2019 represents opportunities for numerous businesses and...







